LATISSE Drug Patent Profile

✉ Email this page to a colleague

Which patents cover Latisse, and when can generic versions of Latisse launch?

Latisse is a drug marketed by Abbvie and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has seventeen patent family members in eight countries.

The generic ingredient in LATISSE is bimatoprost. There are twelve drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the bimatoprost profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Latisse

A generic version of LATISSE was approved as bimatoprost by APOTEX on December 1^st, 2014.

Sign Up

AI Research Assistant

Questions you can ask:

What is the 5 year forecast for LATISSE?
What are the global sales for LATISSE?
What is Average Wholesale Price for LATISSE?

Summary for LATISSE

International Patents:	17
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	74
Clinical Trials:	8
Patent Applications:	4,457
Drug Prices:	Drug price information for LATISSE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for LATISSE
What excipients (inactive ingredients) are in LATISSE?	LATISSE excipients list
DailyMed Link:	LATISSE at DailyMed

Drug patent expirations by year for LATISSE

Recent Clinical Trials for LATISSE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tulane University	Early Phase 1
Allergan	Early Phase 1
Allergan	Phase 3

See all LATISSE clinical trials

Pharmacology for LATISSE

Drug Class	Prostaglandin Analog

Paragraph IV (Patent) Challenges for LATISSE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
LATISSE	Topical Solution	bimatoprost	0.03%	022369	1	2010-05-03

US Patents and Regulatory Information for LATISSE

LATISSE is protected by two US patents.

Patents protecting LATISSE

Method of enhancing hair growth
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF STIMULATING HAIR GROWTH

Method of enhancing hair growth
Patent Number: ⤷ Sign Up
Patent Expiration: ⤷ Sign Up
Patented Use: METHOD OF INCREASING HAIR GROWTH

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	AT	RX	Yes	Yes	⤷ Sign Up	⤷ Sign Up				⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for LATISSE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	⤷ Sign Up	⤷ Sign Up
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	⤷ Sign Up	⤷ Sign Up
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	⤷ Sign Up	⤷ Sign Up
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	⤷ Sign Up	⤷ Sign Up
Abbvie	LATISSE	bimatoprost	SOLUTION/DROPS;TOPICAL	022369-001	Dec 24, 2008	⤷ Sign Up	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

EU/EMA Drug Approvals for LATISSE

Subscribe to access the full database, or Sign Up
Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
AbbVie Deutschland GmbH & Co. KG	Lumigan	bimatoprost	EMEA/H/C/000391 Reduction of elevated intraocular pressure in chronic open-angle glaucoma and ocular hypertension (as monotherapy or as adjunctive therapy to beta-blockers).,	Authorised	no	no	no	2002-03-08
>Company	>Drugname	>Inn	>Product Number / Indication	>Status	>Generic	>Biosimilar	>Orphan	>Marketing Authorisation	>Marketing Refusal

International Patents for LATISSE

See the table below for patents covering LATISSE around the world.

Subscribe to access the full database, or Sign Up
Country	Patent Number	Title	Estimated Expiration
Denmark	0660716		⤷ Sign Up
World Intellectual Property Organization (WIPO)	0174315		⤷ Sign Up
Japan	2004346080	NON-ACIDIC CYCLOPENTANE HEPTANOIC ACID, 2-CYCLOALKYL OR ARYLALKYL DERIVATIVE AS MEDICINE	⤷ Sign Up
Japan	3681068		⤷ Sign Up
Australia	2272197		⤷ Sign Up
>Country	>Patent Number	>Title	>Estimated Expiration

Supplementary Protection Certificates for LATISSE

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0660716	SPC/GB02/035	United Kingdom	⤷ Sign Up	PRODUCT NAME: BIMATOPROST; REGISTERED: UK EU/1/02/205/001 20020308
0660716	02C0033	France	⤷ Sign Up	PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION:
0660716	90957	Luxembourg	⤷ Sign Up
0660716	SPC023/2002	Ireland	⤷ Sign Up	SPC023/2002: 20040929, EXPIRES: 20170307
0660716	C300099	Netherlands	⤷ Sign Up	PRODUCT NAME: BIMATOPROST; NAT. REGISTRATION NO/DATE: EU/1/02/205/001 20020308; FIRST REGISTRATION: EU/1/02/205/001 20020308
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description